In today’s recent session, 0.95 million shares of the NewAmsterdam Pharma Company NV (NASDAQ:NAMS) have been traded, and its beta is 0.10. Most recently the company’s share price was $20.00, and it changed around -$3.68 or -15.54% from the last close, which brings the market valuation of the company to $1.85B. NAMS at last check was trading at a discount to its 52-week high of $26.35, offering almost -31.75% off that amount. The share price’s 52-week low was $8.90, which indicates that the recent value has risen by an impressive 55.5% since then. We note from NewAmsterdam Pharma Company NV’s average daily trading volume that its 10-day average is 0.67 million shares, with the 3-month average coming to 383.38K.
NewAmsterdam Pharma Company NV stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 0 recommended NAMS as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. NewAmsterdam Pharma Company NV is expected to report earnings per share of -0.48 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NewAmsterdam Pharma Company NV (NASDAQ:NAMS) trade information
Instantly NAMS has been showing red trend so far today with a performance of -15.54% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 25.32 on recent trading dayincreased the stock’s daily price by 21.01%. The company’s shares are currently up 79.05% year-to-date, but still down -18.70% over the last five days. On the other hand, NewAmsterdam Pharma Company NV (NASDAQ:NAMS) is 5.71% up in the 30-day period. We can see from the shorts that 0.72 million shares have been sold at a short interest cover period of 2.92 day(s).
The consensus price target as assigned by Wall Street analysts is $36.5, which translates to bulls needing to increase their stock price by 45.21% from its current value. Analyst projections state that NAMS is forecast to be at a low of $36 and a high of $37.
NewAmsterdam Pharma Company NV (NAMS) estimates and forecasts
NewAmsterdam Pharma Company NV share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 2.15 percent over the past six months and at a 3.72% annual growth rate that is well below the industry average of 16.60%. The year-over-year growth rate is expected to be 133.34%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 1.61M in revenue for the current quarter. Forecasts for the next quarter put sales growth at -100.00%.
NAMS Dividends
NewAmsterdam Pharma Company NV’s next quarterly earnings report is expected to be released in December.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.25% of NewAmsterdam Pharma Company NV shares, and 89.54% of them are in the hands of institutional investors. The stock currently has a share float of 89.77%.
PGIM Jennison Health Sciences Fd and Fidelity Select Portfolios – Pharmaceuticals were the top two Mutual Funds as of Sep 30, 2024. The former held 489.12 shares worth $9.8 million, making up 0.53% of all outstanding shares. On the other hand, Fidelity Select Portfolios – Pharmaceuticals held roughly 330.2 shares worth around $6.61 million, which represents about 0.36% of the total shares outstanding.
